The final, formatted version of the article will be published soon.
CASE REPORT article
Front. Oncol.
Sec. Gastrointestinal Cancers: Colorectal Cancer
Volume 14 - 2024 |
doi: 10.3389/fonc.2024.1451675
This article is part of the Research Topic Targeting and Monitoring Cancer Metabolism: Novel Theranostics for Colorectal Cancer View all 5 articles
The use of nutrigenomics and nutritional biomarkers with standard care of long-term recurrent metastatic rectal cancer: A case report
Provisionally accepted- Department of Clinical Studies and Nutritional Epidemiology, Nutrition Biomed Research Institute, South Melbourne, Victoria, Australia
Introduction: Distant metastases following standard treatment for locally advanced rectal cancer (LARC) are typically associated with poor disease-free survival. We report on a 52-year-old Australian male of Dutch ancestry with no family history of colorectal cancer or significant medical history who experienced bleeding per rectum for several months prior to a colonoscopy in July 2010. He was subsequently diagnosed with Stage IIb LARC. Case Presentation: Despite treatment with curative intent, a distant recurrence to his left lung was detected in May 2012, upstaging him to Stage IV rectal cancer. He had repeated distant metastatic recurrences over the next eight years and treatment included multiple surgeries, chemotherapies, radiation treatments, a 'watch and wait' period of 20 months, and personalised dietary management. Genetic and nutrigenomic testing identified that the case had KRAS and MTHFR mutations. As part of his dietary management, the case also had his levels of folate, vitamin B12, and vitamin D regularly monitored because of his genetic predisposition and history of deficiency for these key nutrients. Apart from changes in his CEA levels, sudden increases in the case's folate levels, inconsistent with dietary exposures preceded detection of each new distant recurrence, with significant decreases in the levels at the next follow-up measurement. Conclusion: A multimodal approach to this case's management appeared to contribute to his long-term survival of nearly 10 years from the initial diagnosis. Multidisciplinary management including the use of additional biomarkers may enhance survival rates in other similar cases with advanced disease resistant to differing therapies, and with potentially poor prognosis.
Keywords: rectal cancer1, Recurrence2, metastasis3, Folate, Nutrigenomics
Received: 19 Jun 2024; Accepted: 07 Nov 2024.
Copyright: © 2024 Brinkman, Crofts and Green. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Maree Brinkman, Department of Clinical Studies and Nutritional Epidemiology, Nutrition Biomed Research Institute, South Melbourne, Victoria, Australia
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.